Low-dose ICV injections of STZ, which do not induce diabetes, have been shown to induce AD-like pathological and behavioral features, such as learning and memory impairments, oxidative stress, neurodegeneration, brain insulin signaling abnormalities, cholinergic disorders, and tau hyperphosphorylation [49, 50]. This evidence concerns the gene MAPT and Alzheimer disease.